Tuesday, April 3, 2018

Allergan, Richter Report Positive Topline Results From Third Cariprazine Trial

Allergan plc (AGN) and Gedeon Richter Plc announced positive topline results for RGH-MD-53, a Phase 3 study of cariprazine for the treatment of adults with major depressive episodes associated with bipolar I disorder or bipolar I depression.

from RTT - Biotech https://ift.tt/2q41hd6
via IFTTT

No comments:

Post a Comment